Key Mesenchymal Precursor Cell Patent Granted in Japan Patent coverage provides for exclusive, long-term commercial rights in major established healthcare market NEW YORK and MELBOURNE, Australia, June 4, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the Japanese Patent Office. Japanese patent number 5265190 provides Mesoblast with exclusive commercial rights in Japan through to September 2025 to all compositions-of-matter and uses of its Mesenchymal Precursor Cell (MPC) technology platform, irrespective of the MPC tissue source, including bone marrow, adipose, placenta, umbilical cord and dental pulp. The granting of the Japanese patent follows the recent extension of compositions-of-matter patents by the United States Patent and Trade Mark Office to March 2029, and two key patents from the State Intellectual Property Office of the People's Republic of China that provide commercial rights and protection through to 2025. The Japanese patent underpins Mesoblast's corporate strategy to protect intellectual property covering its lead clinical products, to safeguard its manufacturing processes and knowledge, and to extend the commercial reach of its proprietary technologies in the world's major markets for regenerative medicines. About Mesoblast Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's technologies include its proprietary Mesenchymal Precursor Cell (MPC) technology platform for bone marrow and adipose tissue derived products, Dental Pulp Stem Cells (DPSCs) and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's allogeneic or 'off-the-shelf' regenerative medicine products focus on repair of damaged issues and modulation of inflammatory responses in conditions with significant unmet medical needs. The lead product candidates use its MPC platform in three major and distinct areas - systemic inflammatory conditions, cardiovascular diseases and orthopedic diseases of the spine. www.mesoblast.com CONTACT: Julie Meldrum Global Head of Corporate Communications Mesoblast Limited T: +61 (0) 3 9639 6036 E: firstname.lastname@example.org
Key Mesenchymal Precursor Cell Patent Granted in Japan
Press spacebar to pause and continue. Press esc to stop.